Intercept Pharmaceuticals Stock EBITDA
| ICPTDelisted Stock | USD 10.31 0.16 1.53% |
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company EBITDA Analysis
Intercept Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Intercept Pharmaceuticals EBITDA | (61.7 M) |
Most of Intercept Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Intercept Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (61.7 Million). This is 107.03% lower than that of the Biotechnology sector and 161.6% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.58% higher than that of the company.
Intercept EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Intercept Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 81.30 % | |||
| Number Of Shares Shorted | 10.19 M | |||
| Price To Earning | (3.88) X | |||
| Price To Book | 44.19 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 285.71 M | |||
| Gross Profit | 284.73 M | |||
| EBITDA | (61.7 M) | |||
| Net Income | (174.86 M) | |||
| Cash And Equivalents | 404.78 M | |||
| Cash Per Share | 13.58 X | |||
| Total Debt | 332.67 M | |||
| Debt To Equity | 411.20 % | |||
| Current Ratio | 3.22 X | |||
| Book Value Per Share | 1.72 X | |||
| Cash Flow From Operations | (26.78 M) | |||
| Short Ratio | 2.64 X | |||
| Earnings Per Share | (4.26) X | |||
| Price To Earnings To Growth | (0.69) X | |||
| Target Price | 19.0 | |||
| Number Of Employees | 341 | |||
| Beta | 0.88 | |||
| Market Capitalization | 794.36 M | |||
| Total Asset | 553.71 M | |||
| Retained Earnings | (2.14 B) | |||
| Working Capital | 310.05 M | |||
| Current Asset | 641.69 M | |||
| Current Liabilities | 47.37 M | |||
| Z Score | -3.15 | |||
| Net Asset | 553.71 M |
About Intercept Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intercept Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intercept Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intercept Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |